Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Naggie S, Cooper C, Saag M, Workowski K, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CAM, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M, for the ION-4 Investigators. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373:705-13. [Ref.ID 99506]
2.Tiene citas relacionadas Cita con resumen
Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki J-P, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AYM, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015;385:1075-86. [Ref.ID 98984]
3.Tiene citas relacionadas
Gane E. Hepatitis C beware—the end is nigh. Lancet 2014;384:1557-60. [Ref.ID 98307]
4.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bomstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heatchcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468-75. [Ref.ID 94919]
5.Tiene citas relacionadas
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, Cosme de Oliveira A, Santoro A, Raoul-J-L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. [Ref.ID 83713]
6.Tiene citas relacionadas
Lai CL, Gane E, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. The authors reply. N Engl J Med 2008;358:1517-8. [Ref.ID 82529]
7.Tiene citas relacionadas
Lai CL, Gane E, Liaw Y-F, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, for the Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88. [Ref.ID 81879]
8.Tiene citas relacionadas Cita con resumen
Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72. [Ref.ID 54336]
9.Tiene citas relacionadas
Gane E, Saliba F, Valdecasas GJC, O'Grady J, Pescovitz M D, Lyman S, Robinson C A. Randomised trial of efficacy and safety or oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33. [Ref.ID 36422]
Seleccionar todas
 
 1 a 9 de 9